{"id":782983,"date":"2023-09-11T07:46:08","date_gmt":"2023-09-11T11:46:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\/"},"modified":"2023-09-11T07:46:08","modified_gmt":"2023-09-11T11:46:08","slug":"eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\/","title":{"rendered":"Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">IRVINE, Calif., Sept.  11, 2023  (GLOBE NEWSWIRE) &#8212; Eledon Pharmaceuticals, Inc. (\u201cEledon\u201d) (NASDAQ: ELDN) today announced the appointment of James Robinson to its Board of Directors effective October 1, 2023. Mr. Robinson is a seasoned biopharmaceutical executive with over 30 years of experience in the industry, most recently serving as Chief Executive Officer and Director of Urovant Sciences until its merger with Sumitomo Pharma America on July 1, 2023.<\/p>\n<p align=\"left\">\u201cI am pleased to welcome Jim to our Board and look forward to working with him,\u201d said David-Alexandre C. Gros, M.D., Chief Executive Officer. \u201cJim joins our Board at a pivotal time in our mission to bring a novel and much-needed new treatment option to the growing number of patients undergoing kidney transplantation. His experience as a leader in the biopharmaceutical industry will be invaluable in this next phase of Eledon\u2019s trajectory.\u201d<\/p>\n<p align=\"left\">As Chief Executive Officer and Director of Urovant Sciences, Mr. Robinson guided the company through FDA approval of its first drug, a successful product launch, and its acquisition and \u201ctake-private\u201d transaction by Sumitomo Dainippon Pharma. Prior to Urovant, he was President and Chief Operating Officer of Paragon Biosciences. Before his time at Paragon, Mr. Robinson served as President and COO of Alkermes, leading operations that generated more than $1 billion in annual revenue. Prior to Alkermes, Mr. Robinson spent over 12 years at Astellas Pharma, one of the leaders in the field of solid organ transplant, where he served as President of the Americas and was responsible for approximately $4 billion in revenue generation.<\/p>\n<p align=\"left\">Mr. Robinson currently serves on the Board of Directors of UroGen Pharma (Nasdaq: URGN). He previously served on the Board of Directors for Neos Therapeutics and for AGTC before the company was sold to Syncona. Mr. Robinson also previously served on the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA), where he served as Chairman of PhRMA\u2019s State Committee. He earned a Bachelor of Science in marketing from DePaul University.<\/p>\n<p align=\"left\">\u201cI am inspired by Eledon\u2019s mission to address a therapeutic area with thousands of patients in need of a better option to protect their transplanted organs,\u201d said Mr. Robinson. \u201cBacked by strong scientific rationale and promising clinical results to date, tegoprubart has the potential to change the outlook for patients with transplanted kidneys and help alleviate shortages of available kidneys by preserving the kidneys in transplant patients. I look forward to leveraging my background and experience while working closely with the Eledon management team to continue advancing tegoprubart through the clinic.\u201d<\/p>\n<p align=\"left\">\n        <strong>About\u00a0Eledon Pharmaceuticals\u00a0and tegoprubart<\/strong>\n      <\/p>\n<p align=\"left\">Eledon Pharmaceuticals\u00a0is a clinical stage biotechnology company with immunology expertise that is developing therapies to protect and prevent rejection of transplanted organs, as well as to treat amyotrophic lateral sclerosis (ALS). The Company\u2019s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in\u00a0Irvine, California. For more information, please visit the company\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=W8PZZ8Sd80m9CigFroFOJBjPgLlxCoCRS7cK7mO4IAB0DN4BwTifr9DPOpG2ogGkvfDupeMp5ZlYUNn6FQ7gA_TvSOchl06kPKuVxEIR4i_LIu_GQr6zzS8I3bE3zvZVhFHSBEh-rNnjfA0_wgA8MPjcIAftHdb539U5NKfva1LTkYDXmvnN0VopRx1wyaz03xkPPbnonj8RQY5pJp-Y_qpLRS9edz0-FvaS5IVy2Vc=\" rel=\"nofollow noopener\" target=\"_blank\">www.eledon.com<\/a>.<\/p>\n<p align=\"left\">Follow\u00a0Eledon Pharmaceuticals\u00a0on social media:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=I1tzSYqaCgV1MH19LHA0085ylol3MYMx89YpjLnhei8XRQAwggH2dPahObwUtgYUaGeXrK_pLL3RT9AJdmX8xVmCTHKbE_px5j8IiO1ovbVx5nHMv2DkbcNk9EtGadMLhWzjXtN_TZXMB__QXycWs5oOPkg0m5A7X5_SHjxOupdiajguhIZKYWub9ehjiy6NDk0HH9uHIs8uvhCXkJsS10cQnEPsubckVK4XdIx-LI0rFMMU2HwWrS5KYf1u1_c1SBU-AlwBYlugUaar1pQ7SGH9o3zzF5hnQ4a3Rm7c0KCwSaZcqK91kykPkS3rugASMr-jLHVoPKXUG8YP78xxRteuZSwNRjCucGzvq1PW6ZRCiJ6U6t8s1aWXqTW6PIFtvZ6Y8Co-es6Bu4AQg6nk-tA2AUYp6ieeZZXZL8uWAFEBzJeaNQnZe04HVK7mBxAd\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>;\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NMv2ixkeU3TvQVn7J0-JN-jQpUFW98mIm8x-AbjskH7aAPSRcFcEGr-xFz_68XtlTyWMsHE0DPk-yU0U0iKjxx_RIXuaC5QzNPjzNQl1yMoCnTvfrYS8aVeoHRsNpAl6eOQE42pYfYFYCc-jbWkqo1jCtYEVNY_DgYJCuQr-ws42gGExKqwFwVGm_XlocJbu05EhAD5jsIyhTJNwjMHkSTJTGJx8CE7ELAG0mhQRn9tyY0MOrGDf_BjHBL59x8Dtpv6ddqSxCF521uV5YPkLhn0hyjpLtDBJ5MyH9QZDYLdnyCNJvXm-2YBCHdaxENmLpwRqRHkGEgwex_7qQpakdaqMKDODrEIV58TmAAgRZv5G_h-TsQMXf30w8rVaoq_3Tpmr4zVMKUzrF1moZhUsy_bHoQdCCPoWPyEQwV2F5kg=\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a><\/p>\n<p align=\"left\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"left\">This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about planned clinical trials and the Company\u2019s other future expectations, plans and prospects, as well as other statements containing the words \u201cbelieves,\u201d \u201canticipates,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201cestimates,\u201d \u201cintends,\u201d \u201cpredicts,\u201d \u201cprojects,\u201d \u201ctargets,\u201d \u201clooks forward,\u201d \u201ccould,\u201d \u201cmay,\u201d and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: risks relating to the safety and efficacy of our drug candidates; risks relating to clinical development timelines, including interactions with regulators and clinical sides, as well as patient enrollment; risks relating to costs of clinical trials and the sufficiency of the company\u2019s capital resources to fund planned clinical trials; and risks associated with the impact of the ongoing coronavirus pandemic. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company\u2019s actual results to differ significantly from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the\u00a0U.S. Securities and Exchange Commission, which can be found at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Qo9Zs_HLZNiMSGtgycFzmgnD2PexpVK6TM0ZCRgFHAYzHNI9MIN99JGWk0pY0qz9LLzU-sWjn-_OHc_K5D3dV6sZxuOl68vieKGrsTuhT7ucdLznXe_fXOdHtyqOk2_In4ve2j_weVK7cGzpnJMCra_DOZrDepEbCbOqqmMfch6y3_hmEdbE1voVkPadELncPXbM3JqMrBD0V0rT-ebIoGjfk4r2aB3yWgAgN2a-iE-eYcHSlL0vLaJ6I3j6WXx-nR92b7f4Gbr0X1cde2sBVXNJ2iSCgHs-Qr1oj2F7LvRoKJyoPz-RbdYYiS03tHIBa0Hw8HAVkMLveoqmyQAJUOA8HhTwfEE_cXU4Of_3bDOtgMKBDs_2QfznMfOk3-rLuNwjR4ceqR5zeepW8FRSXJwnDPx9FdKFKIFL3uq3JXM=\" rel=\"nofollow noopener\" target=\"_blank\">www.sec.gov<\/a>. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n<p align=\"left\">\n        <strong>Investor Contact:<\/strong>\n      <\/p>\n<p align=\"left\">Stephen Jasper<br \/>Gilmartin Group<br \/>(858) 525 2047<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JDdqv4Opg0lLET0fIRtC9c3mNC-5o_uTpALuzPdWIm-1YKNQDPHCcfIPt7MyM4tUe3NnZcKpZrXXumGBhV2say8wjlW8Ry_Y6cIlU52okfjkiTMvDqvXG0PcpenRpaeY6qoABL11nqnpMSvNTvXOODVSCobtkJRfyrVBgt48hhloIKJjj8lIF6vQYjDjApkHSecTvGLl-zBc70pCjCQBtp9nvEDdQErB2_85o2Gl6-ISeoetzC9CWviTbn94otDfdCbt1DYjxPaQoOyqtKiZQQ==\" rel=\"nofollow noopener\" target=\"_blank\">stephen@gilmartinir.com<\/a><\/p>\n<p align=\"left\">\n        <strong>Media Contact:<\/strong>\n      <\/p>\n<p align=\"left\">Jenna Urban<br \/>Berry &amp; Company Public Relations<br \/>(212) 253 8881<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BebityjQ_GWNDtvGkCjwgOEU9l6YbGyuUq0YUJuvSHo3wueKM1VqsfvwVhAFwGHjiYUIdNeBsmESGOTG5HiCPzFgULEPZBF7jyXkVQy-GwgW-Wi7Z7ZXwLuVg_6x6oLkUu-EK8n75uL5It0PGIC1lsdZSxVJRG2yem7bVwik--xdshtoA2d-mgCba3mXSqttR450uqqpTjXQHdyS2WjmeAO-zAyQ_w59Fc9RN7JHsYGrrDXt8KUCYgq2WOwpDno1TQjPcR_vUohtuV7_Nujt7w==\" rel=\"nofollow noopener\" target=\"_blank\">jurban@berrypr.com<\/a><\/p>\n<p align=\"left\">Source:\u00a0Eledon Pharmaceuticals<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxOTY0NiM1ODA2MDY2IzIwMDY1NTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YzNmMTViOGMtMTMxNC00OGRlLWJkNjMtZGUyMDNkNmQwYzQyLTEwMTgxMjM=\/tiny\/Eledon-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>IRVINE, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) &#8212; Eledon Pharmaceuticals, Inc. (\u201cEledon\u201d) (NASDAQ: ELDN) today announced the appointment of James Robinson to its Board of Directors effective October 1, 2023. Mr. Robinson is a seasoned biopharmaceutical executive with over 30 years of experience in the industry, most recently serving as Chief Executive Officer and Director of Urovant Sciences until its merger with Sumitomo Pharma America on July 1, 2023. \u201cI am pleased to welcome Jim to our Board and look forward to working with him,\u201d said David-Alexandre C. Gros, M.D., Chief Executive Officer. \u201cJim joins our Board at a pivotal time in our mission to bring a novel and much-needed new treatment option to the growing number of patients undergoing &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-782983","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"IRVINE, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) &#8212; Eledon Pharmaceuticals, Inc. (\u201cEledon\u201d) (NASDAQ: ELDN) today announced the appointment of James Robinson to its Board of Directors effective October 1, 2023. Mr. Robinson is a seasoned biopharmaceutical executive with over 30 years of experience in the industry, most recently serving as Chief Executive Officer and Director of Urovant Sciences until its merger with Sumitomo Pharma America on July 1, 2023. \u201cI am pleased to welcome Jim to our Board and look forward to working with him,\u201d said David-Alexandre C. Gros, M.D., Chief Executive Officer. \u201cJim joins our Board at a pivotal time in our mission to bring a novel and much-needed new treatment option to the growing number of patients undergoing &hellip; Continue reading &quot;Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-11T11:46:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxOTY0NiM1ODA2MDY2IzIwMDY1NTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors\",\"datePublished\":\"2023-09-11T11:46:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\\\/\"},\"wordCount\":799,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxOTY0NiM1ODA2MDY2IzIwMDY1NTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\\\/\",\"name\":\"Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxOTY0NiM1ODA2MDY2IzIwMDY1NTA=\",\"datePublished\":\"2023-09-11T11:46:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxOTY0NiM1ODA2MDY2IzIwMDY1NTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxOTY0NiM1ODA2MDY2IzIwMDY1NTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors - Market Newsdesk","og_description":"IRVINE, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) &#8212; Eledon Pharmaceuticals, Inc. (\u201cEledon\u201d) (NASDAQ: ELDN) today announced the appointment of James Robinson to its Board of Directors effective October 1, 2023. Mr. Robinson is a seasoned biopharmaceutical executive with over 30 years of experience in the industry, most recently serving as Chief Executive Officer and Director of Urovant Sciences until its merger with Sumitomo Pharma America on July 1, 2023. \u201cI am pleased to welcome Jim to our Board and look forward to working with him,\u201d said David-Alexandre C. Gros, M.D., Chief Executive Officer. \u201cJim joins our Board at a pivotal time in our mission to bring a novel and much-needed new treatment option to the growing number of patients undergoing &hellip; Continue reading \"Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-11T11:46:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxOTY0NiM1ODA2MDY2IzIwMDY1NTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors","datePublished":"2023-09-11T11:46:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\/"},"wordCount":799,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxOTY0NiM1ODA2MDY2IzIwMDY1NTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\/","name":"Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxOTY0NiM1ODA2MDY2IzIwMDY1NTA=","datePublished":"2023-09-11T11:46:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxOTY0NiM1ODA2MDY2IzIwMDY1NTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxOTY0NiM1ODA2MDY2IzIwMDY1NTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-appoints-industry-veteran-james-robinson-to-its-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/782983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=782983"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/782983\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=782983"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=782983"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=782983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}